Probuphine Gets FDA Panel Nod But With Labeling Caveats
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for subdermal implant must clearly identify target patient population as opioid-dependent individuals stabilized on low doses of buprenorphine, committee members say.